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ABSTRACT 
In the last decade, new therapies have changed the management of patients with metastatic 
renal cell carcinoma (mRCC) and metastatic castration resistant prostate cancer (mCRPC). 
Although new therapies have improved survival, drug response varies widely with some 
patients not responding to treatment. Unfortunately, traditional assessment of drug response 
with computed tomography (CT) has limitations, and novel biomarkers of treatment response 
are warranted in order to reduce unnecessary side-effects and costs. The general aim of this 
thesis was to identify imaging biomarkers that can help predict the treatment response in 
mRCC and mCRPC.  
In the first study, metabolic changes of tumour lesions detected by 
18
F-Fluorodeoxyglucose 
(FDG) positron emission tomography (PET) and CT (PET/CT) after 14 days of treatment 
predicted the progression-free (PFS) and overall survival (OS) in 32 patients. Metabolic 
response was assessed in several ways revealing that PET parameters measuring FDG uptake 
within a volume had stronger association to outcome than parameters based on single voxel 
analysis. 
In the second study, the benefit of repeated 
11
C-acetate PET/CT was evaluated retrospectively 
to assess response in patients with mCRPC treated with abiraterone acetate. Potential 
association between 
11
C-acetate PET/CT, serum levels of prostate specific antigen (PSA), 
PFS and OS were investigated. 
11
C-acetate PET/CT predicted PFS and OS which may be of 
particular clinical interest in patients who do not exhibit a PSA response to treatment. 
In the third study, the maximal diameter of metastatic lesions originating from mRCC as 
determined by diffusion-weighted magnetic resonance imaging (DWI) were compared with 
the corresponding measurements on CT. These measurements appeared to be in close 
agreement warranting for a larger trial investigating the feasibility of employing DWI in 
clinical trials that follow the Response Evaluation Criteria in Solid Tumours (RECIST 
version 1.1) guideline. 
In conclusion, the novel imaging biomarkers evaluated here have the ability to predict 
response of mRCC and mCRPC to targeted therapies, but need to be validated in a larger 
setting before being implemented into the clinic. 
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2 INTRODUCTION 
 
2.1 DIAGNOSTIC IMAGING AND THE EMERGING ROLE OF MOLECULAR 
IMAGING IN MEDICINE 
 
The era of medical imaging began in 1895 with the discovery of X-rays by the German 
physicist Wilhelm Conrad Röntgen, an achievement for which he was awarded the Nobel 
prize in physics 6 years later. An enormous fascination with the possibility of viewing 
uninvasively inside the human body led to virtually instant utilization of X-rays, before the 
dangers of ionizing radiation were discovered. During the 20th century the development of 
novel modes of imaging such as nuclear medicine (1940s), ultrasound (1960s), computer 
tomography (CT) and magnetic resonance imaging (MRI) (1970s) also exerted great impact 
on medicine and today most medical specialties depend on imaging for diagnosis guiding 
invasive procedures and monitoring disease treatment.  
The 20
th
 century also brought revolutionary new insights into the molecular details of life 
including pathological processes.  The many new tools, including not least medical imaging 
and drugs discovered have improved our ability to cure or at least prolong the life of patients 
with cancer. However, the anatomic or physiological abnormalities indicative of cancer arise 
relatively late in the course of the disease and further improvement is necessary. Molecular 
imaging techniques allow visualization of functional events on a cellular level, and when 
combined with conventional anatomical imaging to achieve what is often referred to as fusion 
imaging, can help reveal the location of a specific event in the organism. 
In the present thesis, the use of novel imaging technologies that combine anatomical 
information with physiological information to monitor the treatment of patients with 
urological malignancies has been evaluated. 
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2.2 UROLOGICAL MALIGNANCIES 
 
All work described here involves patients with renal cell carcinoma (RCC) or prostate cancer 
and a brief introduction to these pathologies follows.  
 
2.2.1 Renal cell carcinoma (RCC) 
RCC, also called hypernephroma or renal cell cancer, arises from the renal cortex (i.e. the 
renal tubules) and is distinct from tumours that form in the transitional epithelium of the renal 
pelvis or in the renal medulla. RCCs are relatively uncommon, with an annual incidence 
today of approximately 1000 cases in Sweden, accounting for around 2 % of all cancers[1], 
with a male-to-female ratio of around 1.6:1[2]. Risk factors include cigarette smoke, obesity, 
hypertension, diabetes mellitus and reproductive factors, while genetic factors are involved in 
approximately 3-4%[2] of all RCC[3]. The World Health Organization (WHO) classifies this 
disease into several subgroups of which clear cell is by far the most common group (around 
85%), followed by papillary (10%), chromophobe (5%) and an unclassified form somewhat 
different from these others. A sarcomatoid subtype seen in all subgroups is considered to be 
an indicator of progressive disease[2]. Non-specific symptoms of RCC include haematuria, 
flank pain, weight loss and fever. RCC is often discovered incidentally, most often when 
conducting abdominal ultrasound or computerized tomography[4].  
If diagnosed at an early stage, when the tumour is still localized to the kidney or within the 
immediate surrounding tissue, RCC can be cured. Overall, the 5-year survival rate for the 70-
80% of Swedish patients without metastases at the time of diagnosis is 83%[1], while the 
corresponding  figure for the others is only 15%. Although, metastatic RCC (mRCC) is 
relatively resistant to chemotherapy and radiation therapy, our increased understanding 
during the last decade of the underlying mechanisms have led to novel specific therapies, so-
called targeted therapies. Thus, the introduction of tyrosine kinase inhibitors (TKIs) that 
target angiogenic pathways such as sorafenib, sunitinib and pazopanib, has improved the 
survival of patients with mRCC.  
CT is the preferred method for imaging RCC today. In most cases a dedicated multi-phase 
CT allows detection, staging and planning for surgery. When metastases are present repeated 
CT examinations are usually performed to monitor treatment.  
The work described here involves patients with either metastatic disease at the time of 
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diagnosis or a disease relapse following curative therapy.  
 
2.2.2 Castration Resistant Prostate Cancer (CRPC) 
 
Prostate cancer, the most common cancer in Sweden, accounts for 1/3 of all malignancies 
among men[5]. In 2014, 10985 cases were diagnosed and around 2500 of these patients died, 
accounting for approximately 5% of all mortalities among Swedish men. The number of 
cases diagnosed each year has been increasing steadily most likely due to the aging 
population and increasing number of PSA tests being performed. Prostate cancer is rare in 
men under 45 years of age, but very common among men older than 80. However, because of 
its slow progression, most men afflicted will not die from this disease.  
A study from USA reported in 2012 that at the time of diagnosis that 80% of patients 
demonstrate localized, 12% loco-regional and 4% metastatic disease[6] (the remaining were 
not staged at diagnosis). In the absence of metastatic spread, curative treatment involving 
surgery or radiotherapy in combination with androgen deprivation therapy (ADT) is initiated. 
It is now well known that prostate cancer cells require testosterone in order to grow, a 
discovery for which Huggins and Hodges received the Nobel Prize in 1967. However, in the 
majority of patients with metastatic prostate cancer, the disease will eventually become 
refractory to all anti-hormonal treatment, a status referred to as androgen-independent or 
castration resistant (the latter term being preferred by the Prostate Cancer Working Group 2 
committee[7]).  
Determination of whether the tumour has spread beyond the prostate gland and to loco-
regional lymph nodes is critical for deciding on a treatment strategy and much effort is 
currently focused on finding a reliable diagnostic imaging technique for this purpose. The 
role of magnetic resonance imaging (MRI) or positron emission tomography (PET) to stage 
local disease is still under investigation. In 2015 Swedish authorities recommended MRI 
before re-biopsy of patients with suspected cancer but with negative first biopsy, and that 
further studies are conducted to determine if MRI should be implanted as a standard pre-
operative routine[8]. 
When prostate cancer spreads, the cells enter the blood and/or lymph vessels which can 
transport them to distant locations to establish metastases[9]. Thus, such metastases are often 
found in regional lymph nodes before they appear in bone, only occasionally being found in 
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visceral organs such as the lungs or liver. Once spread to distant parts of the body, the disease 
becomes incurable. The most common approach to visualize metastatic spread to the skeleton 
is using bone scintigraphy, while visceral metastases are generally diagnosed with CT. 
 
2.3 TARGETED CANCER THERAPIES  
 
Until the late 1990’s with exception of certain hormone blockers, almost all chemotherapeutic 
drugs against cancer were designed to kill proliferating cells, so that they also kill normal 
cells to a certain extent. So-called targeted therapies based on greater understanding of the 
molecular biology of cancer target specific molecules required for cancer cell growth, 
division and/or spread[10]. Targeted therapies are usually cytostatic, blocking the 
proliferation of tumour cells, while chemotherapeutic agents are cytotoxic, killing the cells. In 
recent decades the several types of targeted therapies approved for use in cancer treatment 
include hormone therapies, inhibitors of signal transduction/angiogenesis[11], modulators of 
gene expression[12], immunotherapies[13] and molecules that deliver toxins[14]. Table 1 
below illustrates the new targeted therapies introduced against mRCC and mCRPC. The 
continuously increasing number of therapeutic options makes it even more important to 
identify patients who will not benefit from treatment, potentially by imaging biomarkers of 
response. Imaging can capture not only heterogeneity within one lesion, but also between 
lesions.  
 
Table 1. Drugs that have received FDA approval for treatment of mRCC or mCRPC. Arrow 
indicates timeline. 
Renal cell carcinoma       Prostate cancer 
Agent       FDA approval   Agent      FDA approval 
 
Interleukin-2 (Proleukin)    1992     cabazitaxel (Jevtana)   2010 
sorafenib (Nexavar®)    2005     abiraterone acetate (Zytiga)  2011 
sunitinib (Sutent®)     2006     enzalutamide (Xtandi)   2012 
temsirolimus (Torisel®)    2007     radium 223 dichloride (Xofigo)  2013 
everolimus (Afinitor®)    2009 
bevacizumab (Avastin®)    2009 
pazopanib (Votrient®)    2009 
axitinib (Inlyta®)     2012 
nivolumab (Opdivo®)    2016 
cabozantinib (Cabometyx™)   2016 
lenvatinib mesylate (Lenvima®)   2016 
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2.4 MOLECULAR IMAGING TECHNOLOGIES 
 
In the present research Positron Emission Tomography (PET) in combination with CT 
(PET/CT) utilizing the radiotracers 
18
F-Fluorodeoxyglucose (FDG) and 
11
C-acetate, along 
with Diffusion Weighted MRI (DWI) have been employed.  
 
2.4.1 PET/CT 
PET/CT, one of the most powerful imaging modalities presently available, combines 
functional information obtained with radio-labelled substances with anatomical information 
provided by CT, with the two being superimposed to provide a fusion image. In the case of 
PET, a radio-labelled tracer injected into the body intravenously is then distributed to tissues 
on the basis of its biochemical and pharmacokinetic properties. At some point the isotope will 
decay and emit a positron from the nucleus which will travel a short distance (less than 1 
mm) before losing most of its energy in collisions with electrons. This collision begins the 
conversion of the mass of the electron and positron into electromagnetic energy in the form of 
two gamma photons, each with an energy of 511 keV and travelling in opposite 
directions[15] though the body.  
These photons can be detected by an external PET camera that converts them into a signal. If 
a pair of such detectors record two annihilating photons at the same time their source is 
located along the line connecting these detectors. After adjusting this information for scatter, 
body attenuation and detector properties, a 3D image can be constructed, in which the signal 
intensity of any given volume is proportional to the amount of radionuclide in that particular 
voxel. Thus, PET images are based on radiation emitted outwards from the patient, while CT 
involves transmission of an outside X-ray through the patient’s body. Due to the present 
physical limitation of the technique, the resolution of modern clinical PET scanners is too 
limited to be able to detect micro-metastatic lesions, which is also beyond reach of other 
imaging modalities. 
 
2.4.2 18F-Fluorodeoxyglucose - FDG 
Fluorodeoxyglucose or 2-deoxy-2-(
18
F)fluoro-D-glucose (FDG), a glucose analogue in which 
the 2’-hydroxyl group has been replaced with the radioactive isotope flouorine-18 that emits 
positrons with a half-life time of 110 minutes. FDG, the most common radioactive tracer used 
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in clinical PET examinations and considered to be “the magic bullet” in nuclear medicine, is 
employed in the evaluation of many types of cancers and infectious diseases. Although every 
living cell in the human body requires glucose, many cancer cells exhibit relatively little 
oxidative phosphorylation and are thus more dependent on glycolysis than most other tissues 
(a phenomenon known as the Warburg effect). Hannahan and Weinberg[16] published a 
highly influential article entitled “The hallmarks of cancer” in 2000 and in the updated 
version of this article that appeared in 2011 one of the two hallmarks added was 
“reprogramming of energy metabolism”, i.e. increased metabolism is not only a characteristic 
of, but even an essential necessity for cancer development. Although many different factors 
influence the uptake of FDG, a number of studies have demonstrated a relationship between  
this uptake and the number of cancer cells[17, 18]. After cellular uptake, FDG is 
phosphorylated by intracellular hexokinases to 
18
F-FDG-6-phosphate, which unlike glucose, 
can neither be metabolized further nor exit the cell and thus can serve as a biomarker for 
glucose uptake in the body.  
 
2.4.3 The standardized uptake value SUV 
The raw PET signals can be converted into concentrations by calculating a Standardized 
Uptake Value (SUV), defined for certain image volume, as the tracer concentration 
normalized to the radioactivity administered and body weight (Figure 1). The unit is g/mL, 
but SUV is generally presented as a unitless value, since 1 mL soft tissue has a mass of 
approximately 1 g. If the FDG injected were to be uniformly distributed throughout the body, 
the SUV would be 1 g/mL, regardless of the amount injected or size of the patient. 
The many factors that potentially can influence the SUV include fundamental physical 
limitations such as the spatial resolution and total effective counts of the detector, which 
together determine the signal-to-noise ratio in a PET image [19]. The limited spatial 
resolution leads to a well-known error in partial volume, where small objects display less than 
their actual concentration of tracer[20]. Other factors include the status of the patient (e.g. 
blood glucose level, previous physical exercise or recent chemotherapy), as well as variations 
in the scan protocol and reconstruction parameters used in processing the images[21]. 
Although the maximal SUV, SUVmax, is most commonly used in the clinic, several other 
SUV parameters are also employed. The SUVmean and SUVmax values apply to a specified 
volume-of-interest (VOI). The SUVmean represents the average SUV within a given volume, 
whereas SUVmax is the peak value for one voxel within the same VOI. SUVmean is 
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influenced by the size of the VOI, while SUVmax is not and is therefore less dependent on 
the observers, more reproducible[22] and especially advantageous for small tumours. 
However, the influence of scatter noise is substantial. The metabolic tumour volume (MTV) 
is defined as the volume of tissue for which the SUV is above a certain threshold. Total lesion 
glycolysis (TLG) can be calculated by multiplying the MTV by the SUVmean within the 
same VOI.  
 
2.4.4 PET/CT for response assessment of mRCC 
While FDG PET/CT is widely utilized to evaluate the metabolism of various cancers, this 
approach has not yet received the same attention in connection with mRCC. The obvious 
reasons for this include the fact that mRCC can vary from intense to only mild uptake of 
FDG, similar to that of normal parenchyma and, moreover as a consequence of urinary 
excretion of FDG by the kidneys, tumours can easily be missed. However, FDG PET/CT is 
better at detecting distant metastases than the primary neoplasm, with a pooled sensitivity 
and specificity in a meta-analysis of 91% and 88% compared to 62% and 88% for renal 
lesions [23].  
The approval of several novel anti-angiogenic therapies targeting mRCC has heightened the 
need for novel biomarkers, such as FDG PET/CT, designed to monitor the early response in 
order to customize effective treatment. Today, standard anatomic radiographic CT imaging 
is carried out usually once every three months during therapy. As illustrated in Figure 1 
conventional CT imaging of mRCC is not very effective. The Response Evaluation Criteria 
in Solid Tumors (RECIST) state that only the longest dimensions of no more than five 
lesions (according to the updated RECIST 1.1, further explained in section 2.5) are to be 
analyzed and that sum of these dimensions must differ more than 30% in order to conclude 
that progress or a partial response has occurred. However, a relatively large proportion of 
the patients who benefit from treatment experience only disease stabilization at the 
beginning and show progress later on[24]. Functional molecular imaging such as FDG-
PET/CT can be utilized to assess early changes in tumour metabolism and may thus be 
useful for monitoring clinical efficacy as illustrated in Figure 2.  
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Figure 1. A large metastatic lesion originating from RCC before (left) and after (right) 
three months of treatment. Since tumour size has changed less than 10%, this would be 
classified as stable disease according to RECIST. Nonetheless, there is a significant 
reduction in the amount of peripheral contrast-enhanced viable tumour and an increase in 
central necrosis, indicative of a positive response.  
 
Although several studies have explored sequential PET/CT with FDG as a biomarker of 
response, the role of this approach in evaluating the response of mRCC to treatment is still 
not very clear. In an early investigation in 2009 by Vercellino and colleagues [25] 12 
patients with a total of 29 different metastases were examined with FDG PET/CT at 
baseline and after the first cycle of sunitinib therapy and the response after 3 months 
treatment compared to the CT response as evaluated according to RECIST. Although the 
results were not statistically significant due to the small sample size, a reduction in FDG 
uptake as reflected in the SUVmax appeared to be associated with longer progression-free 
survival (PFS). That same year Lyrdal and co-workers[26] reported that among 10 patients 
(52 lesions) receiving sorafenib and examined by FDG PET/CT before and 1-2 months 
after initiation  of therapy, those with a decrease in FDG uptake (in this case expressed as 
SUVmax and SUVmean) exhibited significantly better overall survival (OS) (18.1 versus 
12.9 months), but with no significant difference in PFS.  
The 12 patients studied by Minamoto et al[27] in 2010  exhibited similar results. Three with 
partial response had significantly longer PFS and OS than those classified as having stable 
and progressive disease. In a larger investigation by Kayani and colleagues[28] in 2011, 43 
patients receiving sunitinib were examined by FDG PET/CT at baseline and after the first 
4-week cycle of treatment, and 39 of these underwent an additional examination after the 
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third cycle. In contrast to previous reports, they observed no significant correlation between 
a reduction in SUVmax in connection with either the first or second examination and either 
PFS or OS. However, patients with a progressive disease after the third cycle demonstrated 
a significantly shorter OS. These authors also reported that both high metabolic activity and 
a large number of metastatic lesions at baseline were associated with shorter OS.  
In 2012 Ueno and co-workers[29] described a similar study on 30 patients with mRCC who 
underwent PET/CT examinations at baseline and after 1 month of treatment with either 
sorafenib or sunitinb. The changes in SUVmax and in lesion diameter as determined by CT 
were combined to classify response as good, intermediate or poor, all of which 
demonstrated statistically significant associations with both PFS and OS. CT alone could 
not predict outcome.  
Critical aspects of assessing drug efficacy are the time required before a detectable effect 
can be expected and whether or not this effect is sustained. In 2010 Lassau et al[30] found 
that comparison of contrast-enhanced ultrasound examinations performed before and after 
initiation of sunitinib treatment revealed detectable effects after as little as 15 days. These 
investigators also found that the time to peak intensity and wash-in were significantly 
associated with drug-free survival and OS. Accordingly, TKIs appear to act rapidly and 
their effects can be visualized within the first month of treatment. 
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Figure 2. Reduction in the metabolic activity of a liver metastasis originating from mRCC 
after one month of treatment with sunitinib. 
 
2.4.5 Imaging Prostate cancer with 11C-acetate PET/CT  
Imaging of prostate cancer is still a challenge. The existing tools, such as bone scintigraphy 
and CT, do not adequately provide the clinical information required for this highly 
heterogeneous disease and the interest for exploring the potential role of PET in this context 
is increasing. A variety of radiolabelled tracers have been and are currently in use for staging 
prostate cancer, the most well characterized of which are 
18
F-FDG, 
18
F/
11
C-choline and 
11
C-
acetate. The latter two visualize lipogenesis and exhibit similar sensitivity and specificity 
with respect to identifying prostate cancer cells. Initially, both were labelled with 
11
C, a 
radionuclide which has a physical half-life time of only 20 min, making them difficult to use 
without a cyclotron available. To obtain a longer half-life 
18
F-labelled derivatives such as 
18
F-
choline have been developed, and reported to be as accurate as the 
11
C labelled compounds 
[31].  
Normally, PET reveals accumulation of 
11
C-acetate in the heart, kidneys, liver, pancreas 
(highest levels), spleen, stomach, bowel and bone marrow. In addition to prostate cancer, 
malignancies with elevated uptake include hepatocellular carcinomas, RCCs, bladder 
carcinoma and brain tumours. 
11
C-Acetate is involved in the synthesis of phospholipids in 
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which fatty acid synthase (FASN), an enzyme up-regulated in prostate cancers, 
participates[32]. More aggressive forms of prostate cancer, with higher Gleason scores, 
display higher levels of FASN[33] activity and enhanced uptake of 
11
C-acetate has recently 
been proposed  to be a surrogate biomarker for sensitivity to inhibitors of FASN[34], which 
suppress cell proliferation, adhesion, migration and invasion[35]. Thus, targeting FASN 
might effectively suppress multiple steps in the progression of prostate cancer. Figure 3 
illustrates a patient with lymph node and bone metastases from prostate cancer.  
Most studies performed to date indicate a limited ability for choline and acetate tracers to 
localize and characterize the primary tumour within the prostate. Another aspect of initial 
detection of prostate tumours is staging of local lymph nodes in high risk patients. One of the 
few investigations in this area[36] found high patient-by-patient sensitivity, but low 
specificity, in combination with low sensitivity, but high specificity with respect to the nodal 
region. These results are in line with studies indicating the high specificity, but low to 
moderate sensitivity of 
18
F/
11
C-choline.  
The ten-year recurrence rate for prostate cancer can be as high as 34% [37]. In most patients 
recurrence will first be reflected in a rise in prostate specific antigen (PSA), usually referred 
to as biochemical recurrence and thereafter metastases are detectable within months to years. 
The evidence indicates a linear relationship between the level of PSA and detection of 
metastases by PET [38].  
In clinical practice bone scintigraphy is most frequently utilized for imaging of prostate 
cancer. In comparison with 
18
F-Flouride PET the latter has shown to have slightly higher 
sensitivity in detecting bone metastases[39]. It is anticipated that choline or acetate PET could 
be expected to be of value in detecting not only bone but also extra-osseous metastases.  
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Figure 3. Elevated uptake of 
11
C -acetate in abdominal lymph node metastases (encircled) 
and a sclerotic bone metastasis (arrow). 
2.4.6 Diffusion weighted magnetic resonance imaging (DWI) 
DWI, a pulse sequence technique in MRI, monitors the random motion of protons in water 
molecules present in tissues, where their diffusion is restricted by interactions with cell 
membranes and macromolecules. Tissues with high cellularity, such as tumours, impede the 
diffusion of water and are seen as bright areas with high signal intensity in DWI images, 
whereas areas with less restriction produce lower signals on such images with high b-
values[40].  
Since DWI can be performed relatively quickly employing routine MRI scanners, this 
technique is widely available, which is one reason for its increasing popularity. Another 
advantage in comparison to CT or PET/CT is that DWI requires no administration of 
exogenous contrast medium or ionizing radiation when desired. Images can be acquired over 
multiple stations that cover the entire body, a concept first introduced by Takahara and 
colleagues in 2004[41], who also employed background signal suppression in this 
connection. During the last decade improvements in both MRI hardware and software, such 
as the continuous moving table, allow whole body MRI examinations to be performed in a 
clinical setting.  
The free-breathing T2 spin-echo echo-planar technique involved in DWI is explained in 
Figure 4.  
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Figure 4. The DWI sequence involves a spin echo sequence with two strong magnetic field 
diffusion gradients applied to opposing sides of a 180-degree refocusing pulse. Moving and 
static protons (the latter only being present in areas with restricted diffusion) will be 
dephased by the first diffusion gradient and only the static protons will rephase when the 
second is applied, while all moving protons dephase randomly. Finally, a signal will arise 
from static protons only. The unit of diffusion weight is referred to as the b-value. This b-
value can be enhanced either by increasing or prolonging the magnetic gradient or allowing 
more time to elapse between application of the gradients. 
 
With small b-values (e.g. 50-100 mm s/mm
2
), water molecules with extensive freedom of 
movement will produce a bright signal. At the same time a large b-value (e.g. 1000 s/mm
2
) is 
required to detect slow-moving water molecules with restricted diffusion. Sometimes, normal 
tissues also produce a strong signal on DWI images, not due to restricted diffusion, but rather 
to a strong T2 signal which shines through, a phenomenon referred to as “T2 shine through”. 
By performing DWI with at least two different b-values, an apparent diffusion coefficient 
(ADC) can be calculated and the problem of T2 shine through avoided.  
The ADC expressed as mm
2
/s is calculated automatically by MRI workstations and the 
results displayed as a map of the degree of diffusion in different tissues. The errors in this 
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calculation can be reduced by applying several b-values. Areas with restricted diffusion, such 
as in tumours are characterized by ADC values that are lower than those of normal tissues, 
which are brighter. The diffusivity in a region-of-interest of the ADC map can be quantified. 
Although malignancies with impeded diffusion are common findings, false-positives include 
inflammatory conditions, normal lymph nodes and areas with poor suppression by fat. An 
example of DWI in a patient with metastatic prostate cancer is illustrated in Figure 5.  
 
 
 
 
Figure 5. A reconstructed inverted 
b-800 s/mm
2
 diffusion weighted 
image of maximal intensity 
showing pathological lymph nodes, 
originating from RCC, as dark 
round areas in the axillary (blue 
arrows) and pelvic regions (green 
arrows).  
 
 
 
 
 
2.4.7 Usage of DWI to assess the response solid tumours to treatment 
Efficient therapy causes tumour cells to die, thereby disrupting the cellular membrane, 
widening the extracellular space and increasing the diffusion of water[42]. Several 
assessments indicate that the ADC after initiation of treatment is associated with the 
therapeutic effect of a drug and might predict outcome [43-45] and, moreover that changes in 
ADC occur earlier than the reduction of tumour size. A challenge with ADCs in tissues is that 
it is influenced by microcirculation of blood in capillaries leading to higher ADCs. With the 
intravoxel incoherent motion (IVIM) concept[46, 47], first described in 1988 by Bihan and 
colleagues, the molecular diffusion of water can be separated from the perfusion in 
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capillaries. Perfusion related diffusion effects become significant only at low b-values, which 
allows diffusion and perfusion to be separated. The vascularity and cellularity of tumours are 
often directly affected by targeted therapies, which are quantifiable by analysis of IVIM 
based analysis.  
From a clinical perspective, whole-body DWI may provide a solution to current unmet needs 
in the evaluation of anticancer drugs. For example, such evaluation of metastatic bone disease 
is particularly challenging in part because, unless accompanied by an measurable 
extramedullary soft-tissue component, bone disease is not considered to be a measurable 
lesion according to the RECIST [48, 49]. Today, bone scintigraphy is applied most widely to 
evaluate bone metastases, but lytic metastases may be masked to this technique if osteoblastic 
reaction is absent[50]. Furthermore, an osteoblastic reaction visualized by bone scintigraphy 
may be healing rather than progressive disease. Whole-body MRI has been reported to be 
more sensitive than bone scintigraphy or FDG PET/CT in detecting bone metastases [51].  
 
2.5 RECIST AND PERCIST   
 
The increasing number of oncological therapies available makes personalization of treatment 
to maximize the benefit to the patient and minimize waste of resources even more urgent. 
When the WHO initially introduced cancer response criteria[52] imaging was mentioned, but 
without specific radiological guidelines. This absence called for change and in 2000, the 
European Organization for Research and Treatment of Cancer (EORTC) and the National 
Cancer Institute of the United States among others, set up a task force in order to unify and 
standardize such criteria, creating RECIST[48]. Standardized classification of response is 
necessary to allow objective comparisons between different sites. 
In 2009 a refined version with several improvements was released (RECIST1.1[49]), 
including a reduction in the number of lesions to be assessed, new standards for measurement 
of lymph nodes and clarification of the terms complete or partial response and disease 
progression. According to RECIST1.1 the target lesions to be followed throughout the course 
of treatment should be selected from among lesions considered to be measurable i.e. with a 
longest dimension >10 mm. As many as five (maximally two per organ) are selected and not 
necessarily the largest, but those that are most well defined and can be measured 
reproducibly. Other lesions can also be assessed, but are not measured and considered to be 
non-target lesions. Lymph nodes are only considered measurable if the short axis exceeds 15 
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mm. Lytic bone lesions with a measureable soft tissue component can be considered 
measurable, while blastic bone lesions are not. If the sum of the dimensions’ increases by 
>20% and more than 5 mm or if the tumour burden in non-target lesions has risen 
substantially, the patient is considered to be experiencing progressive disease (PD). 
In a retrospective comparison between RECIST1.0 and RECIST1.1 involving 62 patients 
with mRCC receiving vascular endothelial growth factor (VEGF) -targeted therapy, fewer 
lesions were measured according to with RECIST1.1 and the best response (Kappa = 0.819) 
and median time to progression was similar [53]. Thus, assessment of fewer lesions with 
RECIST 1.1 is equivalent to applying RECIST1.0. Although this updated version of RECIST 
represents an improvement, assessment of response solely on the basis of anatomical 
measurements has limitations, particularly in connection with metastatic solid tumours, where 
novel treatments rarely cure, but instead prolong survival by acting in a cytostatic rather than 
cytotoxic fashion [54]. These treatments may shut down certain functions in the cancer cell to 
establish a highly desirable long-term stable disease. For example, the RECIST guidelines are 
insensitive for evaluating treatment of gastrointestinal stromal tumours (GIST) with imatinib, 
although this drug shrinks’ tumour slowly, can be highly effective. Therefore, it has been 
recommended that RECIST not be applied to GIST[55] and the response evaluated instead 
employing CT criteria according to Choi or FDG-PET/CT[56, 57].   
For several years now, evidence has been accumulating that indicates FDG-PET could not 
only provide better imaging of tumour response to drugs than CT, but could also improve 
prediction of survival [58]. FDG-PET is mentioned only briefly in RECIST 1.1 and no 
guidance concerning classification of response by PET is provided. In lymphoma FDG-PET 
is used frequently and guidelines for response assessment have been created [59, 60].  
The variety of solid tumours being examined with FDG-PET/CT is increasing rapidly and a 
draft framework of PET response criteria in solid tumours (PERCIST) was proposed by 
Richard Wahl in 2009 [61]. Key components of PERCIST include standardization of PET 
protocols on calibrated scanners [62]. The patient should have fasted for 4-6 hours prior to 
the examination and serum his/her glucose level should be no more than 200 mg/dL. 
Scanning should be performed within 50-70 minutes after injection of FDG and follow-up 
scans within 15 minutes after the baseline scan.  
Instead of assessing SUVmax, it is recommended that the SUV be corrected for lean body 
mass (SUL) and measured as a sphere with a diameter of 1.2 cm in a lesion preferably larger 
than 1.5 cm (to minimize partial volume effects) to produce a region of interest (ROI) with a 
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volume of 1,3 cm
3
 designated SULpeak. The ROI for this SULpeak will usually include the 
maximal SUL pixel without necessarily being centred around this. Only lesions with an SUL 
greater than 1.5 times the average SUL in liver parenchyma + 2 standard deviations of mean 
SULs (measured as a 3 cm diameter ROI) are measured. As with RECIST1.1, as many as five 
lesions (maximally two per organ) are measured, but the response is classified only on the 
basis of the behaviour of the lesion that takes up most FDG. Partial response and progressive 
disease are defined as either a decline or increase of more than 30% together with a 0.8 unit 
alteration in SULpeak respectively. PERCIST1.0 also acknowledges total lesion glycolysis 
(TLG) by recommending that this be recorded routinely and that a 75% increase by the most 
active lesion be considered metabolic progression.  
Since 2009, six publications have compared RECIST1.1 and PERCIST1.0 and a pooled 
analysis (including 268 patients with different forms of cancer) revealed considerable 
discordance between the two [63]. Compared to RECIST1.1, PERCIST1.0 graded tumour 
response as higher in 85 patients and lower in 16 indicating that PERCIST1.0 might be more 
sensitive in this respect. However, it remains to be determined whether this response is of 
prognostic relevance or clinical significance. 
 
2.6 STATISTICAL PROCEDURES  
 
2.6.1 Kaplan Meier survival analysis 
The Kaplan-Meier survival analysis named after Edward Kaplan and Paul Meier in 1958 is a 
non-parametric statistical model used to estimate survival from patient lifetime data [64]. The 
length of time required for a critical event to occur is called survival time. In medical studies 
survival time is usually identical to time-in-study, since patients seldom enter a study at the 
same time. A Kaplan-Meier plot depicts a curve that declines in multiple steps, each of which 
indicates the occurrence of a specified critical event (in medicine, this often being death, 
which explains the designation survival analysis). Patients who for some reason leave the 
study or have not yet experienced the critical event by the end of the study are referred to as 
“censored observations”. A censored observation is indicated in the Kaplan-Meier plot as a 
vertical tick or cross at the time-point of last follow-up. The Kaplan-Meier procedure is 
commonly used to compare two different groups employing the Logrank test, with the null 
hypothesis of no difference between the two groups being equivalent to their having the same 
survival time. The Kaplan-Meier plot is explained further in Figure 6. 
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Figure 6. A Kaplan-Meier plot comparing two different groups. The Logrank test can be 
applied to determine whether there is a significant difference between these two groups as 
(indicated by the p-value in the graph). 
 
2.6.2 The Cox Proportional Hazards Model 
Other survival models often employed in medical statistics are the proportional hazards 
model [65], regression models that describe a hazard function or ratio that varies 
multiplicatively over time in relationship to various covariates. The hazard ratio represents 
the instantaneous risk for an event to occur during a study period, whereas the relative risk is 
cumulative over the entire period. The hazard ratio can also be described as the instantaneous 
probability of a particular event occurring over time in a group of patients compared to the 
corresponding probability for a control group. A hazard ratio equal to one indicates no 
difference in survival between the two groups; a ratio of less than one indicates better 
survival in the study group; and a ratio of more than one that the risk for an event to occur in 
this group is larger. The endpoint can be any dependent variable (e.g. death, remission or 
progression of disease) associated with the covariates (independent variables). It is important 
to realize that a hazard ratio is a relative measure of effect that provides no information 
concerning the absolute risk. Proportional hazards models involve the important assumption 
that the hazard for any one individual is a fixed proportion of the hazard for any other 
individual, which means that if a covariate doubles the risk for an event on the first day, it 
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also doubles the risk for this same event on any other day.  
In 1972 Sir David Cox applied proportional hazards models to survival data by including 
survival time [66], which is also a continuous variable but with the possibility of including 
censored observations, to create the Cox proportional hazards ratio [67]. When applying this 
model in a multivariable analysis (where several explanatory covariates are included), it is 
important to recognize that it is the number of events observed, rather than the number of 
included subjects in the study, decides how many variables are to be included. It has been 
recommended that for each variable included in a multivariable Cox analysis, a minimum of 
10 events should have been observed [67]. In relationship to Kaplan-Meier plots, the hazard 
ratio represents the distance between the two curves.  
 
2.6.3 P-Values, Statistical Power and Confidence Intervals  
The one goal of statistical analysis is to utilize information about a sample of individuals to 
draw a conclusion about the general population of interest. This can be accomplished either 
by testing a hypothesis (with p-values) or estimation (with confidence intervals). With the 
first approach it is necessary to formulate a “null hypothesis” statement e.g., treatment with 
sorafenib has no benefits for patients with mRCC and then try to disprove it. Secondly, a 
level of significance concerning the probability of obtaining a false positive or rejecting the 
null hypothesis even if it is true (a type I error) is chosen. In biomedical research this level is 
often set at 0.05, indicating that it is acceptable to have 5% probability of false positive result.  
Statistical analysis will give a measure on how extreme the observations were, defined as a p-
value. If the p-value is less than the chosen level of significance, the test suggests that the 
observed data is incompatible with the null hypothesis, thus it must be rejected. If a test 
reveals a false negative result and the null hypothesis remains although it is false, a type II 
error has occurred. Type two errors are related to the sensitivity or the so-called power of the 
test.  
The so-called power of a test is defined as 1 minus the sensitivity and reflects the probability 
of obtaining a type II error, i.e. with lower power there is less chance of rejecting a null 
hypothesis that is false. Thus, the power decides the probability of obtaining a statistically 
significant result. Among the factors that influence the power of a test, the most important are 
the level of statistical significance chosen, the expected magnitude of the differences between 
the groups studied and the sample size. If something is known beforehand about the 
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magnitude of the effect and level of significance, a power analysis can be conducted to 
determine the minimal sample size required to detect the effect.  
Statistical testing of a hypothesis reveals whether there is any difference between the groups 
studied, but does not say anything about the nature of size of the difference. Supplementation 
with a confidence interval provides a range of values covering the actual mean difference 
[68]. Typically, a 95% confidence interval (a 5% significance level) is utilized i.e. the range 
containing of the true value with 95% confidence, indicating both the magnitude of the 
difference and any lack of precision in the estimate thereby helping to decide whether the 
difference is of clinical interest.  
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3 AIM OF THESIS  
 
3.1 GENERAL AIM OF THE PRESENT THESIS 
The general objective of this thesis was to identify imaging biomarkers that can help predict 
the response of mRCC and mCRPC to treatment. 
 
3.1.1 Specific Aims 
More specifically, the aims were as follows: 
Study 1 
To determine whether early metabolic alterations in tumour lesions detected by FDG PET/CT 
can predict the PFS and/or OS of patients with mRCC undergoing treatment with an inhibitor 
of tyrosine kinases i.e. sorafenib, sunitinib or pazopanib, and if so, to identify the most 
valuable FDG PET/CT parameters in this context. 
 
Study 2 
To examine whether changes in uptake of 
11
C-acetate as assessed by PET/CT, are correlated 
with the PSA values and prognosis of patients undergoing treatment with abiraterone acetate 
and whether repeated 
11
C-acetate PET/CT provide clinically relevant information that PSA 
values cannot. 
 
Study 3 
To assess whether the size of metastatic lesions originating from RCC as determined by 
diffusion-weighted MRI are consistent with size as determined by CT, as well as to determine 
whether conventional CT can be replaced by DWI in connection with clinical trials 
conducted according to the RECIST 1.1 protocol.  
 
  
29 
4 MATERIALS AND METHODS 
 
A summary of the general methods applied in this thesis including certain aspects of 
particular interest. 
 
4.1 ETHICAL APPROVAL, PATIENT RECRUITMENT AND INFORMED 
CONSENT 
 
Studies 1 and 3 were prospective and conducted with pre-approval by the regional ethical 
committee in Stockholm, Sweden (Dnr 2007/1551-31/3 and Dnr 2013/1216-31/3). All 
participants, recruited by the referring oncologist, provided their written informed consent 
and were free to leave the study at any time.  
Study 2, a retrospective analysis of available clinical material, was also pre-approved (Dnr 
2015/1068-31) by the same ethical committee. Patient consent was not obtained, in part 
because most of the individuals concerned had already died. 
 
4.2 TREATMENT 
 
In Study 1, 39 patients with mRCC underwent repeated FDG PET examinations prior to and 
after treatment with one of the TKIs sorafenib (19), sunitinib (18) or pazopanib (2) between 
2006 and 2010. These drugs block multiple tyrosine kinase receptors e.g., the receptors for 
platelet-derived and vascular endothelial growth factors [69, 70]. Several of these tyrosine 
kinases play a role in both tumour angiogenesis and proliferation. In addition to being 
approved for treatment of mRCC, sorafenib is also approved for therapy of advanced 
hepatocellular and radioactive iodine-resistant thyroid carcinomas, sunitinib for imatinib-
resistant gastrointestinal stromal tumours and pazopanib for soft tissue sarcoma.  
At the beginning of the study, most of the patients recruited were being treated with sorafenib 
secondary to treatment after interferon. During the study treatment recommendations were 
changed and sunitinib became the drug-of-choice for first-line treatment of mRCC. Most of 
the patients recruited thereafter received sunitinib alone, although a few also received 
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sorafenib and pazopanib as second line treatment.  
In Study 2, conducted over a period of one year, 35 patients with mCRPC recruited 
consecutively were examined by 
11
C-acetate PET/CT before and during treatment with 
abiraterone acetate (1000mg/day). This drug suppresses androgen activity, both by inhibiting 
its enzymatic synthesis and blocking the androgen receptor. Abiraterone acetate has been 
approved only for treatment of mCRPC. Among these patients, 30 had received hormone 
treatment and 30 Docetaxel prior to abiraterone acetate. In addition, four patients had 
previously received Radium-223, two Cyclophosphamide and two Mitoxantrone.   
In study 3 five patients with mRCC was treated daily with 800 mg pazopanib as first line 
treatment for mRCC. Pazopanib is a TKI blocking kinases involved in tumour growth and 
angiogenesis.  
 
4.3 THE PET/CT EXAMINATIONS  
 
4.3.1 The FDG PET/CT examinations in Study 1 
To determine whether early metabolic changes can predict PFS and/or OS in patients with 
mRCC, patients underwent PET/CT before and after 14 (n=32) and 28 days (n=30) of 
treatment with sorafenib, sunitinib or pazopanib. Clinical baseline characteristics and 
measures of outcome, including PFS and OS, were compared to the metabolic response 
indicated by PET. 
The first five patients were examined with a PET camera without CT (ECAT EXACT 31 
CTI), whereas all the other examinations were performed at Karolinska University Hospital 
with a PET/CT (Biograph 64 TruePoint, Siemens) with exception of the two patients from 
Uppsala University Hospital, with whom another PET/CT was employed (Discovery ST, GE 
Healthcare). All PET examinations were carried out in accordance with the standard clinical 
protocol in order to maximize SUV accuracy. Approximately one hour after intravenous 
injection of 4MBq FDG/kg (0.1081 mCi/kg), obtained from the in-house cyclotron, scans 
were performed from the base of the skull to the proximal aspects of the thighs. Patient 
weight and blood level of sugar were measured routinely and all subjects were instructed to 
fast for 6 hours prior to the examination. PET acquisition was done in 3D carried out for 3 
minutes for each bed position with normal tidal breathing. A low dose attenuation correction 
CT and a full-dose diagnostic CT with intravenous contrast (tube tension 120kV, pitch 0,8, 
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slice thickness 1,2 mm and rotation speed 0,5 second) were performed. 
All images were analysed retrospectively by a radiologist who had no information concerning 
the clinical or radiological outcome, utilizing the commercial Siemens software provided by 
the PET/CT manufacturer. Two-dimensional circles were drawn around ROIs in the 
transverse plane of metastatic lesions and three-dimensional iso-contour lines drawn around 
the volume with most FDG uptake as displayed in Figure 7. SUVmax was determined from 
the voxel with the highest SUV within the same volume, the MTV as the entire volume 
delineated and total lesion glycolysis as the MTV multiplied by the average SUV within the 
same volume. The arbitrary SUV threshold was set to either 50% of SUVmax or a fixed 
value of 2.5. A 1-cm
3
 spherical ROI was also drawn around the region demonstrating most 
avid FDG uptake and all SUV values were normalized to lean body mass to obtain SULpeak 
as recommended by PERCIST [61].  
 
Figure 7. Encircled ROIs in one metastatic lesion. The single voxel measurement in the 
centre is SUVmax, the entire metabolic volume around a fixed SUV threshold provides 
MTV/TLG and a small spherical volume around the area with most avid FDG uptake gives 
SULpeak. 
 
Metabolic response was defined as at least a 30% reduction in either SUVmax, TLG50% or 
TLG2.5 and metabolic progression as the appearance of new malignant lesions or at least a 
30% increase in SUVmax, TLG50 or TLG2.5 in comparison to baseline. SULpeak was 
assessed in accordance with the PERCIST criteria [61]. As many as five lesions were 
assessed (no more than two per organ) and two parallel analyses conducted, one on all 
changes in target lesions and the other only on the most FDG-avid lesions. Statistical 
comparison of baseline PET characteristics to clinical outcome was also performed.  
 
4.3.2 C11-acetate PET/CT examinations in Study 2  
In order to evaluate monitoring of mCRPC by 
11
C-acetate PET/CT, 60 PET/CT examinations 
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carried out on 30 patients with this disease at the time of initiation and during treatment with 
abiraterone acetate were evaluated retrospectively. In addition, information on blood levels of 
PSA, haemoglobin and alkaline phosphatase was obtained. 
All of the patients were examined with the same PET scanner (Biograph 64 TruePoint, 
Siemens), approximately 23 minutes after injection of 6-700 MBq 
11
C-acetate (produced by 
an in-house cyclotron). All CT assessments were full-tube diagnostic examinations without 
intravenous contrast medium, otherwise performed according to the same standard protocol 
as in Study 1. All examinations extended from the inferior cervical neck to the proximal 
thighs.  
The repeated 
11
C-acetate PET/CT examinations were examined retrospectively by two 
different readers who had no information concerning clinical or radiological outcome. 
Lesions with the characteristic CT appearance (bone sclerosis, enlarged lymph nodes or 
abnormal lesion in an organ) and elevated 
11
C-acetate uptake were classified as metastases. 
To adjust for variations in plasma clearance 
11
C-acetate uptake was expressed relative to a 
tumour-to-liver ratio. The PET response in connection with the follow-up examination was 
assessed both qualitatively (visual grading of all metastatic lesions) and semi-quantitatively 
by measuring the SUVpeak of the lesion demonstrating the most pronounced uptake. The CT 
examination was analysed in accordance with RECIST1.1. In a separate analysis, a bone 
lesion index was calculated employing an automated segmentation algorithm from General 
Electric (GE) by which in areas exhibiting elevated 
11
C-acetate with a SUV >3 and 
corresponding CT attenuation >150 Hounsfield Units (HU), the volume of metastatic lesion 
was measured. This volume was then divided by the total skeletal volume (areas with CT 
attenuation >150 HU) to obtain an index. All evaluations were performed with the PET 
VCAR software from GE Healthcare. 
 
4.4 THE DWI EXAMINATIONS 
 
In an initial attempt to implement DWI in clinical trials performed according to RECIST1.1, 
we compared the number of lesions measured, their sizes, reduction in their size due to 
treatment and finally, inter-observer variability as determined by DWI and CT. For this 
purpose, five patients with mRCC were examined by both CT and DWI on the same day or 
nearby days before and after three months of treatment with pazopanib. 
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All of the DWI examinations in Study 3 were carried out with the same 1,5T MRI system 
(Siemens) according to a free-breathing echo planar imaging protocol, including suppression 
of background body signal designed to distinguish tumour more clearly from normal tissue.  
Multiple phased-array coils covered the thorax and abdomen at 4 or 5 positions and the total 
acquisition time was 15-20 minutes. Axial DWI images with b-values of 50, 400 and 800 
s/mm
2
 were obtained for analysis and for calculating an ADC.  Maximal intensity projection 
images were also reconstructed to enable diagnosis “at a glance”. The CT examinations were 
performed according to standard clinical protocol and all of these images reconstructed to a 
thickness of 5 mm, with 2,5 mm overlap. Three patients received contrast medium 
intravenously during the parenchymal phase. CT was performed on the same day as DWI in 3 
of the 5 patients, with the difference of 6 and 22 days in the other two cases.  
 
4.4.1 Analysis of DWI imaging  
Two readers interpreted the pre- and post-treatment DWI and CT images independently. 
They had no information concerning the clinical outcome and the images were presented to 
them in random order at two different time-points with no information about whether the 
images were acquired pre- or post-treatment. Lesions that appeared obviously malignant on 
CT or exhibited a high signal on b800 images and markedly reduced diffusion on the ADC 
map were selected for assessment. Each reader measured the diameter of as many as 10 
metastatic lesions (the smallest having a diameter of 10 mm) in the transverse plane. The CT 
and DWI results were compared with respect to the number of target lesions measured, the 
size of lesions, size reduction after therapy and inter-observer variability, as shown in Figure 
8.  
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Figure 8. The longest dimension as determined by DWI (to the left) and CT (in centre) was 
measured and compared before and after treatment. An ADC map (to the right) confirmed 
the identification of malignant lesions by DWI.  
 
4.5 STATISTICAL ANALYSES  
 
The Kaplan-Meier procedure and Cox proportional hazards model were employed to estimate 
and describe survival from lifetime data in Studies 1 and 2. Confidence intervals and p-values 
were calculated. The Spearman Rho test was applied to investigate non-parametric 
correlations between PET response and PSA in Study 2. The non-parametric Wilcoxon 
signed-rank test was utilized for comparison of the median differences between the PSA 
scores in Study 2, as well as the number of lesions measured by the two different readers, 
tumour length before and after treatment, and inter-observer variability in Study 3. All 
statistical analyses were performed with the IBM SPSS software (version 21 and 22). PFS 
was defined as the period that elapsed from enrolment in the study to the date on which the 
patient experienced an event associated with disease progression (e.g., a laboratory test and/or 
radiological or clinical assessment). PFS is sometimes considered to be a surrogate for OS, 
the most reliable endpoint in clinical studies. PFS is usually evaluated when OS data are not 
available.  
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5 RESULTS AND DISCUSSION  
 
5.1 STUDY 1: MONITORING MRCC WITH FDG PET/CT 
 
Although FDG-PET/CT uptake by mRCC is known to be variable [71, 72], PET/CT was 
performed before and after treatment with a TKI in order to examine whether early metabolic 
changes can predict outcome. In our cohort, univariate Cox regression analysis revealed that 
high metabolic activity in the most FDG-avid lesion prior to treatment was negatively 
associated with survival. Moreover, the clinical Heng factor score [73] was significantly 
associated with outcome. These findings are consistent with previous reports [28, 74, 75], 
although we observed no association between Eastern Cooperative Oncology Group (ECOG) 
status or previous treatment and outcome.  
The metabolic response in connection with the follow-up PET/CT examinations (as indicated 
by SULpeak, TLG2.5 and TLG50 14 and 28 days after initiation of treatment) was 
significantly associated with PFS and OS, although SUVmax was not. The largest study on 
FDG-PET/CT monitoring of TKI treatment of RCC (n=44) conducted to date (Kayani et 
al[28]) failed to show any association between FDG-PET response and outcome after one 
month of treatment, but a negative association between elevated FDG uptake and survival 
after three months of treatment. A key difference between this investigation and ours is that 
these other researchers classified the PET response on the basis of the SUVmax for the most 
FDG-avid lesion.  Studies on patients with GIST have provided strong evidence that FDG-
PET can be used for early prediction of the response of such tumours to TKI [76-78]. For 
example, Prior and co-workers were able to predict PFS employing the volume based 
SUVpeak for the three most FDG-avid lesions after 4 weeks of treatment with sunitinib [79], 
of course there may be essential biological differences between mRCC and GIST in this 
context, but it is also possible that the single most FDG-avid voxel, as reflected in SUVmax, 
chosen from only one of a patient’s many metastases might not be representative of the 
response by a widespread and heterogeneous mRCC. As shown in Figure 9, SUVmax is still 
the PET parameter most commonly utilized, although there is also growing interest in 
volume-based parameters such as metabolic tumour volume, total lesion glycolysis and the 
SUVpeak.  
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Figure 9. Usage of different PET parameters in articles published between 2007 and 2016.  
 
Although we found that the metabolic response as assessed by PET can predict PFS and OS, 
our study does have several limitations. The number of individuals evaluated was relatively 
small and five of the patients underwent their examinations on a PET scanner without an 
attached diagnostic CT, so in these cases only the changes detected by PET were utilized to 
assess the response. Moreover, our patients received three different TKIs, although all three 
do inhibit anti-angiogenesis by blocking the VEGF receptor-2. Some received the treatment 
as second-line therapy, although a separate analysis excluding such patients also revealed an 
association between metabolic response and OS.  
Finally, our definition of response/progress as at least a 30% metabolic change or the 
appearance of new lesions on PET was somewhat arbitrary. There is currently no consensus 
concerning how to define the metabolic response of mRCC on the basis of PET/CT 
examinations. The PERCIST classification proposed attempts to establish a new standard, by 
measuring the average SUV within a small volume of the most FDG-avid region of the 
metastatic lesion. Our present findings support the introduction of new SUV parameters such 
as those proposed by PERCIST, but also of total lesion glycolysis in this context. In a recent 
investigation of patients with follicular lymphoma prediction of treatment failure improved 
when total body metabolic tumour volumes were assessed [80].  
The timing of imaging is another key and unresolved issue. In most cases PET/CT is 
performed at the end of the first cycle of therapy, while patients are still receiving treatment, 
in order to avoid a rebound increase in FDG uptake, a phenomenon previously described in 
connection with treatment of GIST with imatinib [81].  Recently, Horn and colleagues [82] 
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compared FDG and FLT PET results for 19 patients with mRCC after 0, 1, 2 and 3 weeks of 
sunitinib treatment. They showed an immediate and sustained proliferative (FLT) response 
after one week of therapy, but with weaker prognostic value than the metabolic response (the 
average SUVmax for as many as six metastatic lesions on FDG PET), which required at least 
two weeks of treatment.  
Although our results indicate little difference between the results of assessment from 2 to 4 
weeks after initiation of treatment, these findings need to be confirmed in a larger trial in 
which several different PET parameters are assessed. Preferably, a larger cohort of treatment 
naïve patients with mRCC who is about to start treatment with a targeted therapy would 
conduct a FDG PET/CT together with another imaging modality (DWI or contrast-enhanced 
ultrasound) before and after three weeks of treatment.  
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5.2 STUDY 2: MONITORING CRPC WITH 11C-ACETATE PET/CT 
 
Although the therapeutic options for patients with mCRPC are increasing rapidly and a 
variety of techniques are currently used to diagnose recurrent and metastatic disease, none 
has gained a dominant role in all clinical scenarios. Serum PSA, an established biochemical 
marker, demonstrate relatively good correlation to total tumour burden, but limited value in 
explaining clinical symptoms or for planning subsequent radiotherapy.  
In study 2, 10 patients exhibited partial response (PR), 10 stable disease (SD) and 10 
progressive disease (PD) upon comparison of the second PET/CT to the first. Those 
exhibiting a PET/CT response had significantly longer PFS and OS. For the 19 patients with 
a measurable target lesion on CT when treatment was initiated the corresponding numbers 
were 4, 10 and 5 (PR/SD/PD) while the remaining 11 patients had only sclerotic bone 
metastases that could not be assessed according to RECIST. A PSA response, defined as a 
reduction in the serum level by more than 50%, occurred in 14 patients, of whom all but one 
experienced partial response or stable disease as assessed by PET/CT.  
More importantly, in the subgroup of patients without a PSA response, the OS of those 
demonstrating PD on PET/CT differed from that of those with controlled disease (PR or SD). 
Thus, 
11
C-acetate PET/CT is of potential clinical value for patients in whom no PSA response 
occurs. At the same time, the need of 
11
C-acetate PET for general monitoring of mCRPC is 
arguable, since at least in the current investigation the outcome could be predicted equally 
well on the basis of CT alone and PSA. However, in cases where the PSA response is not 
clear and only bone metastases are present, 
11
C-acetate PET/CT could play a key role in 
assessing response. It is also not yet known the extent to which expression of FASN, which 
enzymatic activity is upregulated in aggressive forms of prostate cancer[33], can serve as a 
surrogate biomarker for the response of mCRPC to treatment which might enhance interest in 
11
C-acetate as a radiotracer.  
This study also had several limitations. The cohort consisted of only thirty patients and some 
of these had already received several different treatments prior initiation of abiraterone 
acetate. In addition, the inter-individual variation in 
11
C-acetate uptake by normal tissues 
required adjustment. Although we could not find any substantial evidence in the literature 
that 
11
C-acetate uptake by metastatic lesions differs from that by normal tissues, this remains 
a hypothesis.  
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5.3 STUDY 3: MONITORING MRCC WITH DWI 
 
Our third study was designed to examine whether DWI can be incorporated into radiological 
assessments of response that follow the RECIST1.1 guideline. In addition to not requiring 
any intravenous contrast medium or ionizing radiation, DWI can provide quantitative 
information concerning the diffusivity of tissues (ADC-map), an aspect currently being 
investigated extensively [83-85]. ADC reporting is not mentioned in RECIST1.1, and the 
logical first step before implementing DWI in clinical trials would be to determine whether 
measurement of tumour size as measured by DWI is reliable and in agreement with the 
corresponding values obtained by CT.  
The five patients in Study 3 underwent both CT and DWI examinations in close proximity in 
time before and after three months of treatment. There were no significant differences in the 
number of lesions measured per subject. A reduction in median tumour size was observed 
with both approaches (from 32 to 29 mm with CT and from 30 mm to 28 mm with DWI). 
There was no statistically significant difference when each lesion was assessed pre- and/or 
post-treatment by the same reader on the basis of CT and DWI. Although the inter-observer 
variability in connection with pre-treatment CT and pre- and post- treatment DWI was the 
same, there was a significant difference between readers in connection with post-treatment 
CT. A methodological consideration was that pulmonary metastases under influence of 
motion artefacts were measured frequently (only lymph node metastases were measured more 
frequently), which could have influenced measured dimensions. Another consideration is the 
possible underestimation of tumour size on follow-up examinations due to necrosis induced 
by treatment. This could be the reason why we found a larger mean difference between size 
of the same lesion measured by CT and DWI on post-treatment (1.76 mm) examinations than 
pre-treatment (1.31 mm) examinations. 
This pilot indicates that further investigation of the applicability of DWI in RECIST1.1 trials 
is warranted. Because of the small number of individuals examined there was an obvious risk 
of a type II statistical error due to under-powering. Nonetheless, these results provide 
important information for deciding sample size in connection with a larger trial. In a post-hoc 
power analysis, we calculated that comparison of 2536 lesions is required in order detect any 
significant difference between measurement by DWI and CT that might exist. One way to 
overcome the sample size problem in a larger trial, is to choose another form of cancer than 
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mRCC. Breast cancer could be a suitable candidate, considering it metastasizes as solid 
tumours in various organs and the increasing number of therapeutic options. In the present 
study we employed measurements on DWI images with a b-value of 800. However, this 
value was arbitrary chosen whether this or other b-values correspond best to measurements 
by CT has to be further investigated. It could also be of interest to use several b-values, that 
makes it possible to extrapolate a computed b-value of desired magnitude, which may show 
higher agreement to CT than that of b-value 800.  
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6 SUMMARY OF FINDINGS 
 
The following conclusions can be drawn from the work described here: 
FDG-PET/CT can potentially provide a surrogate biomarker for the response of mRCC to 
treatment with TKIs. Selection of the appropriate PET parameters appears to be of crucial 
importance in this context and parameters including PET volume may be more reliable than 
those based only on the highest pixel value. 
Repeated 
11
C-acetate PET/CT examinations can predict the clinical outcome of patients with 
mCRPC undergoing treatment with abiraterone acetate. Although CT and serum PSA can 
predict this outcome, CT fails to assess response in the large number of patient with bone 
metastases only and PSA provides no information concerning the localization of tumour 
burden.  
Measurements on mRCC by DWI or CT appear to be in close agreement and initiation of a 
larger trial investigating the feasibility of employing DWI in clinical trials that follow the 
RECIST1.1 guideline is warranted. 
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7 FUTURE PERSPECTIVES AND CHALLENGES 
 
As a consequence of innovations in the fields of molecular biology and technology, 
molecular imaging is showing ever-greater promise. Hybrid PET/CT technology is standard 
in many hospitals and PET/MRI is on the move from the laboratory to the clinic. Better 
availability of scanners allows the introduction of more novel and specific 
radiopharmaceuticals that fill present needs.  
Despite its known drawbacks and the fact that it only reveals the basic metabolism of tissues, 
FDG has definitely become a blockbuster for nuclear medicine and is continuously proving to 
be valuable in more and more aspects of daily clinical work. Although FDG-PET has been 
around for quite some time, many questions concerning interpretation of the results obtained 
still remain to be answered, as demonstrated by this thesis. We can expect larger studies in 
this area in the future going hand in hand with the introduction of novel oncological PET 
tracers. The superior image resolution and better quantification by PET (5-7 mm) than with 
single photon emission computed tomography (SPECT) (12-15 mm) favour the former, 
although the longer half-lives time of the isotopes employed by SPECT enable labelling of 
antibodies, fragments of antibodies or peptides for investigating biodistribution, targeting and 
drug kinetics. 
Some of the radiotracers of tomorrow have already been approved and are available, but their 
clinical usefulness has yet to be proven. 
18
F-Fluorothymidine (FLT), a non-metabolized 
thymidine analogue, can serve as a tracer for tumour proliferation, but the fact that its uptake 
into tumours is relatively low compared to that of FDG has so far limited its clinical use. This 
situation might change as more cytostatic therapies are introduced and novel biomarkers of 
tumour proliferation become desirable.  
Hypoxia is another target for experimental imaging and among the several different tracers 
available, 
18
F-misonidazole (FMISO) is by far the most commonly used. Tumour hypoxia 
may promote tumour progression and has been associated with failure of radio- and 
chemotherapy [86, 87]. Although hypoxia, as visualized by FMISO, has not yet been shown 
to be correlated with clinical outcome [88], such information might help in planning 
treatment in the future. Although, tracers for metabolism (FDG), proliferation (FLT) and 
hypoxia (FMISO) can provide insight into tumour behaviour, these are still relatively non-
specific and development of a tracer that binds to a specific receptor expressed uniquely on 
the surface of cancer cells is highly desirable. 
68
Ga coupled to prostate specific membrane 
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antigen (PSMA), which binds to surface proteins on prostate cancer cells, has recently shown 
high potential for localizing the tumour within the prostate  (87.5% accuracy) [89], as well as 
distant metastatic lesions in patients with a PSA value of < 0.5 ng/mL [90].  
In the case of breast cancer several attempts have been made to image specific therapeutic 
targets, including estrogen receptors, the human epidermal growth factor receptor 2 (HER2) 
receptor, the epidermal growth factor receptor and receptors involved in angiogenesis. 
Trastuzumab, an antibody targeting HER2, has dramatically improved therapy for HER2-
positive patients. In a recent publication from 2016 small affibody molecules labelled with 
68
Ga were utilized to reveal HER2 expression in patients with metastatic breast cancer [91]. If 
cancer cells can be distinguished definitely from normal tissue, it might be possible to follow-
up a diagnostic PET examination with a therapeutic one involving a radionuclide with 
therapeutic properties, such as 
177
Lu.  
The field of body DWI has expanded rapidly during the last decade and is today not only 
subject extensive research but also widely applied in clinical practice. MRI systems are 
continuously improving in hardware and pulse sequence and a variety of platforms are in use. 
The technological difference between MRI systems has created reproducibility issues that 
remain a challenge, and in order to gain interest as a biomarker reproducible quantification is 
essential. While early diffusion measurement protocols only employed a monoexponential 
model, consisting of only two b-values, modern clinical MRI scanners employ protocols with 
multiple b-values including very high values (exceeding 2000 s/mm
2
 as in diffusion kurtosis 
imaging). This enables measurement of capillary perfusion and other flow phenomena [92], 
but at the price of longer scan times. Optimal number of b-values, and what b-values to 
select, are still unknown and more reports concerning this issue are to be expected. 
Considering that DWI does not expose patients to any intravenous contrast media or ionizing 
radiation, repeated examinations for assessment of tumour response to oncological treatment 
may be in favour of DWI to CT. In particular, metastases of the bone (for example from 
breast or prostate cancer) represent an area with unmet clinical need for a robust biomarker. 
Bone metastases can be assessed rapidly by assessment of maximum intensity projections 
images displaying high b-value signal reductions accompanied by rises in ADC [93], and it is 
possible that this technique will replace conventional bone scans in the future. 
PET/MRI combines the morphological, functional and molecular imaging potential of MRI 
and PET. DWI provides PET/MRI with new potential concerning information on tissue 
structure and biology, that are not possible with PET/CT [94]. For example, DWI may be 
complementary to PET when examination is focused on finding small metastases of the liver, 
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where pathological FDG uptake is often blurred by physiological uptake. However, the most 
exciting potential might not lie in lesion detection, but rather in combining information from 
PET tracers more specific than FDG, for example FLT might come out negative concerning 
the tumour proliferation while the lesion is picked-up with DWI.   
It is desirable that the next generation of agents for molecular imaging allow accurate 
visualization of the extent of the primary tumour (for correct staging), early diagnosing of 
metastatic disease (making salvage treatment a realistic option), prediction of the response to 
planned treatment (as a support in decision making) and finally, assessment of the early 
response to any given treatment (to make it possible to change the treatment regime for non-
responders).  
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